Low High-Sensitivity C-Reactive Protein Level in Korean Patients With Chronic Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW-CKD

Changhyun Lee, Keun Hyung Park, Young Su Joo, Ki Heon Nam, Tae-Ik Chang, Ea Wha Kang, Joongyub Lee, Yun Kyu Oh, Ji Yong Jung, Curie Ahn, Kyu-Beck Lee, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han, Changhyun Lee, Keun Hyung Park, Young Su Joo, Ki Heon Nam, Tae-Ik Chang, Ea Wha Kang, Joongyub Lee, Yun Kyu Oh, Ji Yong Jung, Curie Ahn, Kyu-Beck Lee, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han

Abstract

Background Inflammation levels are lower in East Asians than in Western people. We studied the association between high-sensitivity hs-CRP (C-reactive protein) and adverse outcomes in Korean patients with chronic kidney disease. Methods and Results We included 2018 participants from the KNOW-CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) between April 2011 and February 2016. The primary outcome was a composite of extended major cardiovascular events (eMACE) or all-cause mortality. The secondary end points were separate outcomes of eMACE, all-cause death, and adverse kidney outcome. We also evaluated predictive ability of hs-CRP for the primary outcome. The median hs-CRP level was 0.60 mg/L. During the mean follow-up of 3.9 years, there were 125 (6.2%) eMACEs and 80 (4.0%) deaths. In multivariable Cox analysis after adjustment of confounders, there was a graded association of hs-CRP with the primary outcome. The hazard ratios for hs-CRPs of 1.0 to 2.99 and ≥3.0 mg/L were 1.33 (95% CI, 0.87-2.03) and 2.08 (95% CI, 1.30-3.33) compared with the hs-CRP of <1.0 mg/L. In secondary outcomes, this association was consistent for eMACE and all-cause death; however, hs-CRP was not associated with adverse kidney outcomes. Finally, prediction models failed to show improvement of predictive performance of hs-CRP compared with conventional factors. Conclusions In Korean patients with chronic kidney disease, the hs-CRP level was low and significantly associated with higher risks of eMACEs and mortality. However, hs-CRP did not associate with adverse kidney outcome, and the predictive performance of hs-CRP was not strong. Registration URL: http://www.clinicaltrials.gov; Unique identifier: NCT01630486.

Keywords: cardiovascular events; chronic kidney disease; hs‐CRP; kidney outcome; mortality.

Conflict of interest statement

None.

Figures

Figure 1. Cumulative incidence curve for (…
Figure 1. Cumulative incidence curve for (A) the primary and individual secondary outcomes of (B) eMACE, (C) all‐cause mortality, and (D) composite renal outcome according to hs‐CRP group.
eMACE indicates extended major cardiovascular events; and hs‐CRP, high‐sensitivity C‐reactive protein.
Figure 2. Forest plot for subgroup analysis.
Figure 2. Forest plot for subgroup analysis.
BMI indicates body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; and LDL‐C, low‐density lipoprotein cholesterol.

References

    1. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ, Weiner DE. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130–1136.
    1. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis. 2009;204:298–303.
    1. George LK, Koshy SKG, Molnar MZ, Thomas F, Lu JL, Kalantar‐Zadeh K, Kovesdy CP. Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail. 2017;10:e003825 DOI: 10.1161/CIRCHEARTFAILURE.116.003825.
    1. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739–751.
    1. Fischer MJ, Kimmel PL, Greene T, Gassman JJ, Wang X, Brooks DH, Charleston J, Dowie D, Thornley‐Brown D, Cooper LA, et al. Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease. Kidney Int. 2011;80:670–678.
    1. He J, Shlipak M, Anderson A, Roy JA, Feldman HI, Kallem RR, Kanthety R, Kusek JW, Ojo A, Rahman M, et al. Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) Study. J Am Heart Assoc. 2017;6:e005336 DOI: 10.1161/JAHA.116.005336.
    1. Shin JH, Kang KW, Kim JG, Lee SJ. Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation. Kidney Res Clin Pract. 2018;37:130–137.
    1. Lee C, Yun HR, Joo YS, Lee S, Kim J, Nam KH, Jhee JH, Park JT, Yoo TH, Kang SW, et al. Framingham risk score and risk of incident chronic kidney disease: a community‐based prospective cohort study. Kidney Res Clin Pract. 2019;38:49–59.
    1. Howcroft TK, Campisi J, Louis GB, Smith MT, Wise B, Wyss‐Coray T, Augustine AD, McElhaney JE, Kohanski R, Sierra F. The role of inflammation in age‐related disease. Aging (Albany NY). 2013;5:84–93.
    1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143.
    1. Gupta NK, de Lemos JA, Ayers CR, Abdullah SM, McGuire DK, Khera A. The relationship between C‐reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. J Am Coll Cardiol. 2012;60:1148–1155.
    1. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C‐reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta‐analysis. Lancet. 2010;375:132–140.
    1. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C‐reactive protein as a risk factor for coronary heart disease: a systematic review and meta‐analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483–495.
    1. Sung KC, Ryu S, Chang Y, Byrne CD, Kim SH. C‐reactive protein and risk of cardiovascular and all‐cause mortality in 268 803 East Asians. Eur Heart J. 2014;35:1809–1816.
    1. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68:237–245.
    1. Hung AM, Ikizler TA, Griffin MR, Glenn K, Greevy RA, Grijalva CG, Siew ED, Crawford DC. CRP polymorphisms and chronic kidney disease in the third National Health and Nutrition Examination Survey. BMC Med Genet. 2011;12:65.
    1. Fried L, Solomon C, Shlipak M, Seliger S, Stehman‐Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184–3191.
    1. Kelley‐Hedgepeth A, Lloyd‐Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, Sternfeld B, Pasternak RC, Chae CU. Ethnic differences in C‐reactive protein concentrations. Clin Chem. 2008;54:1027–1037.
    1. Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A. C‐reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis. 2009;207:291–297.
    1. Jiang S, Bao Y, Hou X, Fang Q, Wang C, Pan J, Zuo Y, Zhong W, Xiang K, Jia W. Serum C‐reactive protein and risk of cardiovascular events in middle‐aged and older Chinese population. Am J Cardiol. 2009;103:1727–1731.
    1. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM. Gender and C‐reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152:593–598.
    1. Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X. Distributions of C‐reactive protein and its association with metabolic syndrome in middle‐aged and older Chinese people. J Am Coll Cardiol. 2007;49:1798–1805.
    1. Kim H, Yoo TH, Choi KH, Oh KH, Lee J, Kim SW, Kim TH, Sung S, Han SH. Baseline cardiovascular characteristics of adult patients with chronic kidney disease from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW‐CKD). J Korean Med Sci. 2017;32:231–239.
    1. Oh KH, Park SK, Park HC, Chin HJ, Chae DW, Choi KH, Han SH, Yoo TH, Lee K, Kim YS, et al. KNOW‐CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods. BMC Nephrol. 2014;15:80.
    1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
    1. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170:244–256.
    1. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013;28:2670–2677.
    1. Ridker PM, Bassuk SS, Toth PP. C‐reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep. 2003;5:341–349.
    1. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High‐sensitivity C‐reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7‐year follow‐up study. Diabetes Care. 2006;29:329–333.
    1. Clearfield MB. C‐reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc. 2005;105:409–416.
    1. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C‐reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397.
    1. Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases. Int J Mol Sci. 2019;20:1599.
    1. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7:1938–1946.
    1. Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, Rahman M, Lash JP, Townsend RR, Ojo A, et al. Inflammation and progression of CKD: the CRIC Study. Clin J Am Soc Nephrol. 2016;11:1546–1556.
    1. Liu Y, Wang J, Zhang L, Wang C, Wu J, Zhou Y, Gao X, Wang A, Wu S, Zhao X. Relationship between C‐reactive protein and stroke: a large prospective community based study. PLoS One. 2014;9:e107017.
    1. Sugiyama T, Ishikawa S, Kotani K, Gotoh T, Itoh Y, Kayaba K, Kajii E. Relationship between serum high‐sensitivity C‐reactive protein and myocardial infarction in a general Japanese population. J Clin Lab Anal. 2016;30:999–1002.
    1. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida A. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227–234.
    1. Denker M, Boyle S, Anderson AH, Appel LJ, Chen J, Fink JC, Flack J, Go AS, Horwitz E, Hsu CY, et al. Chronic Renal Insufficiency Cohort Study (CRIC): overview and summary of selected findings. Clin J Am Soc Nephrol. 2015;10:2073–2083.
    1. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445–1452.
    1. Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS. Serum C‐reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int. 2002;62:2208–2215.
    1. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O'Donnell CJ, Kathiresan S, Meigs JB, Keaney JF Jr, Rong J, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant. 2011;26:920–926.
    1. Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, Tsai MY, Cruickshanks KJ, Schubert CR, Brazy PC, et al. Markers of inflammation predict the long‐term risk of developing chronic kidney disease: a population‐based cohort study. Kidney Int. 2011;80:1231–1238.
    1. Saito I, Sato S, Nakamura M, Kokubo Y, Mannami T, Adachi H, Konishi M, Okada K, Iso H, Kario K, et al. A low level of C‐reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC‐Collaborative Inflammation Cohort (JNIC) study. Atherosclerosis. 2007;194:238–244.
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
    1. Fliotsos M, Zhao D, Rao VN, Ndumele CE, Guallar E, Burke GL, Vaidya D, Delaney JCA, Michos ED. body mass index from early‐, mid‐, and older‐adulthood and risk of heart failure and atherosclerotic cardiovascular disease: MESA. J Am Heart Assoc. 2018;7:e009599 DOI: 10.1161/JAHA.118.009599.
    1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med. 2008;359:2195–2207.
    1. Amdur RL, Feldman HI, Dominic EA, Anderson AH, Beddhu S, Rahman M, Wolf M, Reilly M, Ojo A, Townsend RR, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC Study. Am J Kidney Dis. 2019;73:344–353.
    1. Lash JP, Ricardo AC, Roy J, Deo R, Fischer M, Flack J, He J, Keane M, Lora C, Ojo A, et al. Race/ethnicity and cardiovascular outcomes in adults with CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies. Am J Kidney Dis. 2016;68:545–553.
    1. Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, Marre M, Hamet P, Patel A, Poulter N, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63:1115–1123.
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
    1. Hayashino Y, Mashitani T, Tsujii S, Ishii H. Elevated levels of hs‐CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care. 2014;37:2459–2465.
    1. Inaguma D, Imai E, Takeuchi A, Ohashi Y, Watanabe T, Nitta K, Akizawa T, Matsuo S, Makino H, Hishida A. Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD‐JAC) study. Clin Exp Nephrol. 2017;21:446–456.
    1. Seo SM, Baek SH, Jeon HK, Kang SM, Kim DS, Kim WS, Kim HS, Rha SW, Park JS, Seong IW, et al. Correlations between the level of high‐sensitivity C‐reactive protein and cardiovascular risk factors in Korean adults with cardiovascular disease or diabetes mellitus: the CALLISTO study. J Atheroscler Thromb. 2013;20:616–622.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera